Abstract
Introduction Parkinson’s disease is characterized, in part, by hypoactivity of both direct pathway inhibitory projections from striatum to the globus pallidus internus (GPi) and indirect pathway inhibitory projections from globus pallidus externus (GPe) to the subthalamic nucleus (STN), giving rise to disrupted basal ganglia circuit activity. In this study, we explored the use of intracranial stimulation for eliciting long-term potentiation (LTP) of each of these pathologically underactive inhibitory projections for the restoration of basal ganglia circuit dynamics and amelioration of motor symptoms.
Methods Data were collected from a total of 31 people with Parkinson’s disease (42 hemispheres). During deep brain stimulation (DBS) surgery, we assessed microelectrode stimulation-induced changes to inhibitory evoked field potentials (fEP) and hand kinematics before versus after a 40-second train of high-frequency stimulation (HFS) in the GPi (n = 7, 11 sites at 100 Hz) and STN (n = 10, 14 sites at 100 Hz; n = 4, 7 sites at 180 Hz). Additionally, we assessed changes to beta oscillations and hand kinematics in people with chronic DBS implants in the GPi (n = 6 at 125 Hz) and STN (n = 4 at 180 Hz).
Results Intraoperatively, increases in fEP amplitude (p = 0.002) and improved motor performance (p = 0.003) were observed after 100 Hz HFS in the GPi; while in STN, HFS did not potentiate fEPs (p = 0.589) or improve motor performance (p = 0.460) (similar results yielded for 180 Hz in STN). Similarly, extraoperative GPi-DBS produced suppression of beta power (p=0.096) and motor improvement (p = 0.077) before versus after HFS at 125 Hz; while STN-DBS at 180 Hz did not significantly affect beta power (p = 0.267) or motor performance (p=0.850).
Interpretation Our findings support that LTP-like effects in GPi may produce motor improvements that extend beyond stimulation cessation, aligning with optogenetic studies showing long-lasting motor recovery through periodic D1-striatal activation in rodents. The lack of effects in STN suggests that stimulation paradigms may require optimization for effective LTP induction. These findings nevertheless highlight the potential of LTP-based strategies for sustained therapeutic benefits in Parkinson’s disease, warranting further investigation into periodic stimulation paradigms for optimizing DBS efficacy and side effect profiles.
Competing Interest Statement
L.M. and W.D.H. hold intellectual property related to predicting and modelling neuronal responses to DBS (patent publication number: 20220152396; application number: 17/527,042). All other authors declare no competing interests related to this work.
Funding Statement
This project has been made possible with financial support from Parkinson Canada (L.M.), the Natural Sciences and Engineering Council (NSERC) RGPIN-2022-05181 (L.M.), the Canadian Institute for Health Research (CIHR) PJT 191880 (L.M., S.K., A.F.), and the Ontario Graduate Scholarship (K.A.S.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University Health Network Research Ethics Board gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at https://osf.io/am2q8/
